Geratherm announces preliminary financial figures 2019

Publication of an insider information pursuant to article 17 of MAR transmitted by DGAP – a service of EQS Group AG

Geratherm Medical: High growth in sales and results in the first half of 2020, especially in the second quarter

  • Strong international demand for Geratherm medical devices for Corona prevention
  • Sales revenues 13.9 million EUR + 29.4 %, second quarter +71.5 %
  •  EBITDA 2,052 kEUR + 36.0 %, second quarter 1,381 kEUR
  • EBIT 1,454 kEUR +54.2 %, second quarter 1,082 kEUR
  • EBIT margin 10.5 %, second quarter 14.2 %
  • Results of normal business activity 1,403 kEUR + 46.5 %, second quarter 
  • 1,055 kEUR
  • Earnings per share 21 cents (previous year: 11 cents), second quarter 15 cents 

Geratal, 12 August 2020 – In the course of the international spread of the Corona pandemic, there was a high demand for Geratherm devices during the last months. There was a growth in sales for the entire company of +71.5 % in the second quarter. All the business segments indicated a high growth in sales. The demand is still higher than the supply, so that we can assume a continuation of the positive corporate 
development. The detailed half-year report will be published on 20 August 2020.

Geratherm Medical AG
Firmensitz: Fahrenheitstraße 1, 99331 Geratal
Registergericht: Amtsgericht Jena, HRB 111272
Vorstand: Dr. Gert Frank
Aufsichtsratsvorsitzender: Dipl.-Kfm. Rudolf Bröcker
Tel. 036205/98 0
E-Mail: info@geratherm.com
www.geratherm.com

Short company profil:
Geratherm Medical is an internationally operating medical products enterprise with the business areas Healthcare Diagnostic, 
Medical Warming Systems, Cardio/Stroke and Respiratory. Our company’s roots are in temperature measurement in the medical 
sphere. In this business area we offer a broad spectrum of products, most of which have unique selling points. We supply our
customers/patients with high-quality products ranging from thermometers to complex warming systems for use in the operating 
theatre and by emergency rescue services and MR Diagnostic Incubator Systems for premature babies and newborns. In the 
Cardio business area we concentrate on the development of products for the detection of atrial fibrillation as a measure to prevent 
strokes. The Respiratory segment develops and markets products for the assessment of pulmonary function. In all mainly business 
areas, Geratherm has patent-protected basic technologies at its disposal. We regard ourselves as a research-based medical 
products company with a clear focus on medical diagnostic devices that generate vital data. Geratherm shares have been listed in 
the Prime Standard segment of the Frankfurt Stock Exchange since the year 2000. Geratherm Medical continues to be 
represented in the German Entrepreneurial Index and in the German Healthcare Index

Back